Xtant Medical Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Xtant Medical Holdings wird ein Gewinn- und Umsatzwachstum von 57.4% bzw. 16.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 59.1% pro Jahr wachsen soll.

Wichtige Informationen

57.4%

Wachstumsrate der Gewinne

59.1%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.6%
Wachstumsrate der Einnahmen	16.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186%

Mar 02

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:XTNT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	163	4	N/A	N/A	1
12/31/2025	134	-1	N/A	2	2
12/31/2024	118	-10	-3	N/A	2
3/31/2024	101	-2	-15	-13	N/A
12/31/2023	91	1	-11	-10	N/A
9/30/2023	78	3	-12	-11	N/A
6/30/2023	68	-9	-11	-9	N/A
3/31/2023	63	-8	-8	-7	N/A
12/31/2022	58	-8	-7	-5	N/A
9/30/2022	57	-9	-5	-3	N/A
6/30/2022	56	-8	-3	-1	N/A
3/31/2022	56	-7	-1	1	N/A
12/31/2021	55	-5	-2	0	N/A
9/30/2021	55	-3	-1	1	N/A
6/30/2021	56	-3	0	2	N/A
3/31/2021	51	-5	-2	0	N/A
12/31/2020	53	-7	-2	-1	N/A
9/30/2020	56	-8	-3	-2	N/A
6/30/2020	58	-8	-4	-3	N/A
3/31/2020	63	-8	-4	-3	N/A
12/31/2019	65	-8	-1	0	N/A
9/30/2019	66	-63	1	2	N/A
6/30/2019	68	-65	1	2	N/A
3/31/2019	71	-68	1	1	N/A
12/31/2018	72	-70	1	1	N/A
9/30/2018	73	-42	-1	0	N/A
6/30/2018	76	-47	0	1	N/A
3/31/2018	78	-52	-2	-1	N/A
12/31/2017	83	-52	N/A	-1	N/A
9/30/2017	88	-29	N/A	-4	N/A
6/30/2017	91	-25	N/A	-7	N/A
3/31/2017	91	-20	N/A	-15	N/A
12/31/2016	90	-19	N/A	-14	N/A
9/30/2016	88	-3	N/A	-11	N/A
6/30/2016	82	-5	N/A	-13	N/A
3/31/2016	71	-4	N/A	-6	N/A
12/31/2015	59	-2	N/A	-9	N/A
9/30/2015	46	-17	N/A	-11	N/A
6/30/2015	37	-12	N/A	-8	N/A
3/31/2015	36	-11	N/A	-7	N/A
12/31/2014	35	-11	N/A	-7	N/A
9/30/2014	35	-11	N/A	-5	N/A
6/30/2014	34	-15	N/A	-5	N/A
3/31/2014	33	-15	N/A	-5	N/A
12/31/2013	33	-13	N/A	-5	N/A
9/30/2013	33	-13	N/A	-8	N/A
6/30/2013	34	-12	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: XTNT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: XTNT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: XTNT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: XTNTDie Einnahmen des Unternehmens (16.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: XTNTDie Einnahmen des Unternehmens (16.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von XTNT in 3 Jahren voraussichtlich hoch sein wird

Xtant Medical Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 27% to US$2.35

Consensus EPS estimates fall by 33%

Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024

Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Consensus revenue estimates increase by 17%

Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023

Recent updates

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024

New minor risk - Profitability

Price target increased by 27% to US$2.35

Consensus EPS estimates fall by 33%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024

Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds

Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds

Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Consensus revenue estimates increase by 17%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023

Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Consensus EPS estimates fall by 17%, revenue upgraded

Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Consensus EPS estimates upgraded to US$0.06 loss

Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xtant Medical Holdings, Inc. Announces Executive Changes

Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021)

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023

Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021)

Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022

Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding

Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021)

Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020)

Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186%

New 90-day high: US$4.26

Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019)

Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding

Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: US$1.84

New 90-day high: US$1.52

Third quarter earnings released

Third-quarter earnings released: Earnings beat expectations, revenue disappoints

New 90-day high: US$1.63

Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards

Xtant Medical Holdings, Inc. announced that it expects to receive $62.882 million in funding

New 90-day low: US$0.76

New 90-day low - US$0.87

First half earnings released

Xtant Medical Holdings, Inc. to Report Q2, 2020 Results on Aug 03, 2020

Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Growth Index

Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Index